NIBR is relaunching its Neuroscience group in Cambridge to focus on innovative science that leads to the discovery and development of new drugs for neuropsychiatric and neurodegenerative diseases.
Our approach puts science first. We are focused on using human genetics, stem cell models, optogenetics and other novel technologies to understand and treat neuropsychiatric and neurodegenerative disease. Our long-standing strategy is to focus on diseases in which we have a clear genetic and mechanistic understanding without regard to the size of the patient population.
Leadership & Team
We can use the best science to advance our understanding of disease biology and improve people’s lives. There are very few things that are more noble than that.
Ricardo Dolmetsch, Global Head of Neuroscience, NIBR
Global Head of Neuroscience, NIBR
Ricardo Dolmetsch is Global Head of Neuroscience at the Novartis Institutes for BioMedical Research. His group is responsible for leveraging advances in human genetics to model and treat neuropsychiatric and neurodegenerative diseases. The areas of focus include genomics, induced pluripotent stem cells and brain circuitry.
Ricardo joined Novartis in August 2013 from the Stanford University School of Medicine and the Allen Institute for Brain Science. His lab studied the underlying cellular and molecular basis of autism and other neurodevelopmental disorders. His group developed some of the first induced pluripotent stem cell models of neuronal and cardiac disease and made important contributions to understanding calcium channel biology. Ricardo received his B.Sc. from Brown University, his Ph.D. from Stanford University and was a postdoctoral fellow at Harvard Medical School. He was awarded the Society for Neuroscience Young Investigator Award and the NIH Director’s Pioneer Award for his work on calcium channels and iPSC models.